Bayer HealthCare

Bayer initiates expanded access program for radium-223 chloride

Monday, February 6, 2012 02:11 PM

The FDA has approved of Bayer Healthcare proceeding with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.

More... »

Regeneron, Bayer initiate phase III SIGHT trial in China

Monday, November 28, 2011 10:30 AM

Regeneron Pharmaceuticals and Bayer HealthCare have initiated a phase III clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

More... »

MediSapiens, Bayer HealthCare collaborate in oncology

Tuesday, October 11, 2011 01:01 PM

MediSapiens and Bayer HealthCare Pharmaceuticals have agreed to develop a platform for genomics data management and analysis in oncology.

More... »

Bayer’s phase III prostate cancer trial meets primary endpoint

Tuesday, September 27, 2011 11:39 AM

Bayer HealthCare Pharmaceuticals has reported that the investigational drug radium-223 chloride showed positive data in the phase III ALSYMPCA (ALpharadin in SYMptomatic prostate cancer) trial. The study met its primary endpoint by significantly improving overall survival by 44% in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. All of the main secondary efficacy endpoints analyzed to date were met, including delay in skeletal-related events (SREs).

More... »

The CenterWatch Monthly, June 2011

Wednesday, June 1, 2011 01:51 PM

Sites rate Novo Nordisk, Roche, Amgen on top

More... »

Bayer to cut 540 jobs

Friday, May 27, 2011 12:23 PM

Bayer HealthCare is ending production of its multiple sclerosis drug Betaseron in Emeryville, Calif. and taking it to Germany, according to Fierce Pharma. The production move will cut about 540 jobs.  Betaseron will be produced under a contract with Boehringer Ingelheim.

More... »

Regeneron/Bayer reveal positive results for CRVO study

Friday, April 29, 2011 11:22 AM

Regeneron Pharmaceuticals and Bayer HealthCare reveal positive results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the phase III GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). 

More... »

Bayer will consolidate in New Jersey

Tuesday, April 5, 2011 02:41 PM

Bayer HealthCare has selected New Jersey as the place to consolidate its East-Coast business site.

More... »

Bayer reports interim results of safety study on oral contraceptives

Tuesday, March 29, 2011 12:59 PM

Bayer HealthCare Pharmaceuticals announced interim results from a large, prospective, observational cohort safety study that offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as “the pill.”

More... »

FDA approves Bayer's Gadavist injection for MRI

Friday, March 18, 2011 10:32 AM

Bayer HealthCare Pharmaceuticals said the FDA has approved Gadavist (gadobutrol) injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).

More... »